Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956727 | 0.77 | CCNA2 (0.39) | CCNA2CDK2CDK1CCNB1HRH4 | |
| SCHEMBL4956728 | 0.77 | CCNA2 (0.39) | CCNA2CDK2CDK1CCNB1HRH4 | |
| SCHEMBL4958939 | 0.76 | HRH4 (0.36) | CCNA2CDK2CDK1CCNB1HRH4 | |
| SCHEMBL5358288 | 0.73 | ALDH1A1 (0.34) | CCNA2CDK2CDK1CCNB1HRH4 | |
| SCHEMBL5366207 | 0.72 | HRH4 (0.39) | CCNA2CDK2CDK1CCNB1HRH4 | |
| SCHEMBL4954191 | 0.72 | HRH4 (0.39) | CCNA2CDK2CDK1CCNB1HRH4 | |
| SCHEMBL4954810 | 0.72 | CCNA2 (0.36) | CCNA2CDK2CDK1CCNB1HRH4 | |
| SCHEMBL20404186 | 0.67 | CYP1A2 (0.47) | — | |
| Hydrochloric Acid SCHEMBL17186497 | 0.60 | PNP (0.51) | — | |
| SCHEMBL5373078 | 0.59 | METAP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285543-B2 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | DANG QUN | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | FBP1, PNP, PPA1 | CCNA2 3629/4885CDK2 1590/4885CDK1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.